CMRA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CMRA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Comera Life Sciences Holdings's revenue for the three months ended in Sep. 2023 was $0.14 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $1.00 Mil. Comera Life Sciences Holdings's Revenue per Share for the three months ended in Sep. 2023 was $0.01. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.05.
During the past 12 months, the average Revenue per Share Growth Rate of Comera Life Sciences Holdings was 23.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
The historical data trend for Comera Life Sciences Holdings's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Comera Life Sciences Holdings Annual Data | |||||||
Trend | Dec20 | Dec21 | Dec22 | ||||
Revenue | 0.44 | 0.32 | 0.63 |
Comera Life Sciences Holdings Quarterly Data | |||||||||||
Dec20 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Revenue | Get a 7-Day Free Trial | 0.24 | 0.16 | 0.39 | 0.32 | 0.14 |
For the Biotechnology subindustry, Comera Life Sciences Holdings's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Comera Life Sciences Holdings's Revenue distribution charts can be found below:
* The bar in red indicates where Comera Life Sciences Holdings's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Comera Life Sciences Holdings (OTCPK:CMRA) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Thank you for viewing the detailed overview of Comera Life Sciences Holdings's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael Gerard Campbell | officer: Chief Financial Officer | C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801 |
Charles Cherington | 10 percent owner | ONE BOW STREET, CAMBRIDGE MA 02138 |
David Soane | 10 percent owner | C/O SOANE LABS, LLC, 380 NE 72ND TERRACE, MIAMI FL 33138 |
Robert Patrick Mahoney | officer: Chief Scientific Officer | 12 GILL STREET, SUITE 4650, WOBURN MA 01801 |
Barbara K Finck | director | C/O PROTINE DESIGN LAB, 3858 JACKSON ST, SAN FRANCISCO CA 94118 |
Kirsten Flowers | director | C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130 |
James Sherblom | director | 12 GILL STREET, SUITE 4650, WOBURN MA 01801 |
Stuart A Randle | director | 585 WEST 500 SOUTH, BOUNTIFUL UT 84010 |
Sullivan Edward Aloysius Jr. | director | 12 GILL STREET, SUITE 4650, WOBURN MA 01801 |
Sirshendu Roopom Banerjee | director | 12 GILL STREET, SUITE 4650, WOBURN MA 01801 |
Janice Mccourt | officer: Chief Business Officer | C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801 |
Jeffrey S. Hackman | director, officer: See Remarks | 12 GILL STREET, SUITE 4650, WOBURN MA 01801 |
John D. Yee | director | 12 GILL STREET, SUITE 4650, WOBURN MA 01801 |
Neal Muni | officer: See Remarks | 12 GILL STREET, SUITE 4650, WOBURN MA 01801 |
Phoenix Venture Partners Lp | 10 percent owner | 36 DOCKSIDE CIRCLE, REDWOOD SHORES CA 94065 |
From GuruFocus
By Value_Insider Value_Insider • 11-09-2022
By Stock market mentor Stock market mentor • 01-04-2023
By Marketwired • 07-20-2023
By Marketwired • 08-08-2023
By Stock market mentor Stock market mentor • 01-12-2023
By Ds*** Ds*** • 08-31-2022
By Marketwired • 09-12-2023
By Marketwired • 08-01-2023
By Marketwired • 08-16-2023
By Business Wire Business Wire • 06-16-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.